Skip to main content

Research Repository

Advanced Search

Myocardial fibrosis in stroke survivors

Wong, K.; Sze, S.; Wong, S.; McSwiggan, S.; Allgar, V.; MacWalter, R.; Struthers, A. D.


K. Wong

S. Sze

S. Wong

S. McSwiggan

V. Allgar

R. MacWalter

A. D. Struthers


Stroke survivors are most likely to die of cardiac death, yet few undergo comprehensive cardiac assessment to look for reversible causes. Myocardial fibrosis (MF) is not only the hallmark of cardiomyopathy, but also a substrate for sudden cardiac death, ventricular tachyarrhythmia and heart failure. Procollagen carboxyl-terminal telopeptide (PICP) was found to be a marker of MF. The relationship between PICP and cardiac abnormalities in stroke survivors is unknown. We recently showed that MF in stroke survivors can be treated by spironolactone and amiloride in a randomised placebo-controlled cross-over study with reduction in PICP levels and QTc [1].


Wong, K., Sze, S., Wong, S., McSwiggan, S., Allgar, V., MacWalter, R., & Struthers, A. D. (2015). Myocardial fibrosis in stroke survivors. International journal of cardiology, 187(1), 138-140.

Journal Article Type Article
Acceptance Date Mar 17, 2015
Online Publication Date Mar 19, 2015
Publication Date May 6, 2015
Deposit Date Apr 8, 2015
Publicly Available Date Apr 8, 2015
Journal International journal of cardiology
Print ISSN 0167-5273
Electronic ISSN 1874-1754
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 187
Issue 1
Pages 138-140
Keywords Myocardial fibrosis, PICP, Stroke survivors
Public URL
Publisher URL
Additional Information Author's accepted manuscript of article which has been published in International journal of cardiology, 2015, v.187.


Article.pdf (134 Kb)

Copyright Statement
© 2016, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International

You might also like

Downloadable Citations